Marco A. Magalhães, Ron Waksman, Augusto D. Pichard
Insuficiencia Aórtica post TAVI
Cesar Moris2014-10-30 Profesor CardiologíaDirector Departamento del CorazónHospital Universitario Central de AsturiasUniversidad de OviedoOVIEDO — ESPAÑA
TAVI en insuficiencia aórtica
Cesar Moris2014-10-30 Profesor CardiologíaDirector Departamento del CorazónHospital Universitario Central de AsturiasUniversidad de OviedoOVIEDO — ESPAÑA
Short-Term Outcomes of TAVR in Asymptomatic or Minimally Symptomatic Patients
Aortic valve replacement (AVR) is indicated for symptomatic aortic stenosis (AS), while close follow-up is recommended for asymptomatic patients, unless they have elevated aortic gradients, low ejection fraction, or abnormal stress tests. However, the optimal timing to perform AVR is uncertain, especially with recent evidence suggesting that patients with AS associated with signs of myocardial<a href="https://solaci.org/en/2024/02/21/short-term-outcomes-of-tavr-in-asymptomatic-or-minimally-symptomatic-patients/" title="Read more" >...</a>
MyVal Device in Non-Calcified Severe Aortic Regurgitation
Due to the proven long-term results and substantial increase in the number of transcatheter aortic valve implantation (TAVI) procedures conducted, the application of TAVI has been extended to clinical situations outside the original scope, such as non-calcified aortic regurgitation (NCAR). Device placement in these new scenarios entails a technical challenge due to the absence of<a href="https://solaci.org/en/2023/08/23/myval-device-in-non-calcified-severe-aortic-regurgitation/" title="Read more" >...</a>
New Devices for Percutaneous Treatment of Native Aortic Regurgitation: Expanding Horizons
Severe aortic regurgitation (AR) may account for 20% to 30% of all surgical aortic valve replacements (SAVR) and is often associated with aortic stenosis (AS). Transcatheter treatment of these patients is limited due to anatomical factors such as root and annular dilation, large annular dimensions, and less calcification in the valve leaflets to serve as<a href="https://solaci.org/en/2023/06/26/new-devices-for-percutaneous-treatment-of-native-aortic-regurgitation-expanding-horizons/" title="Read more" >...</a>
Medical vs. Endovascular Treatment in Uncomplicated Type B Aortic Dissection
Under much debate, the treatment of uncomplicated type B aortic dissection is still uncertain. Several studies with methodological limitations have shown that endovascular treatment plus optimal medical treatment might be beneficial, compared with medical treatment alone. This meta-analysis sought to define more clearly the treatment strategy in patients with acute and subacute uncomplicated type B<a href="https://solaci.org/en/2020/01/21/medical-vs-endovascular-treatment-in-uncomplicated-type-b-aortic-dissection/" title="Read more" >...</a>
TAVR Offers Better Quality of Life to Low Risk Patients
Courtesy of Dr. Carlos Fava. As we all know, TAVR is gaining ground fast in the lower risk patient population, but in addition to analyzing the most important events, researchers are increasingly looking at health status, not only at hospital level, but also after one year. This study looked into PARTNER 3 patient health status<a href="https://solaci.org/en/2019/10/16/tavr-offers-better-quality-of-life-to-low-risk-patients/" title="Read more" >...</a>
The FDA Affirms Mortality Signs with Paclitaxel Based Devices
Evidently, we are still uncertain. The information goes both ways, even on our own web page, we have been coming and going just like any other publication around the world. After a 2-day debate, the Circulatory System Devices FDA panel has confirmed the tendency to higher mortality with paclitaxel-based devices and is expected to debate<a href="https://solaci.org/en/2019/06/19/the-fda-affirms-mortality-signs-with-paclitaxel-based-devices/" title="Read more" >...</a>
TAVR in Pure Aortic Regurgitation: New Devices, New Outcomes
Pure aortic regurgitation has historically been considered a contraindication for transcatheter aortic valve replacement (TAVR) due to the absence of calcification and subsequent device anchoring problems it poses. Initial reports on first-generation self-expanding valves for the treatment of pure regurgitation were somewhat discouraging, but devices evolved, adding repositioning capacity, different external skirts (pericardial, PET, urethane,<a href="https://solaci.org/en/2017/12/26/tavr-in-pure-aortic-regurgitation-new-devices-new-outcomes/" title="Read more" >...</a>
- 1
- 2